- Elon Musk threatens to release damning information on Twitter’s internal discussions about the decision to censor the Hunter Biden lap top story.
- Fauci leaves with no apologies. Here is why apologies are needed.
- Scott Atlas: Drs. Anthony Fauci and Deborah Birx, as well as academics who supported lockdown measures, have left behind a harmful legacy that Americans are still grappling with today.
- New Biden regulations threaten to turn Medicaid into “Welfare for All”.
- Which is better: Medicare or Medicare Advantage? NYT gives a biased view.
From my latest column at Forbes:
Consider the effect of having one insurer cover drugs, while the other two are covering medical care. If a diabetic skips his insulin and other medications, that is actually profitable for the drug insurer – since these are expenses it doesn’t have to cover. However, if such non-adherence to a drug regimen leads to emergency room visits and hospitalization, those are costs the other two insurers will have to bear.
- What if the FTC truth-in-advertising law applied to Congress? CBO: The inflation Reduction Act will have a negligible effect on inflation.
- Nurses leaving the ER for Botox.
- Company wants a cell or two from you, so it can grow an embryo and harvest organs. HT: Tyler Ghoulish
- Since Democrats need every vote to pass their IRA bill, their new approach to Covid in Congress is: “Don’t ask, don’t tell.”
- The controversy over SSRIs has become political. But shouldn’t we all want to know what antidepressants mass shooters were on when they opened up on innocent victims?
Antibiotic-resistant bacterial infections are a growing. Worse yet, the pipeline of new antibiotic drugs in development are few and far between. It’s been several years since the U.S. Food and Drug Administration (FDA) approved a new antibiotic. The FDA recently declined to approve two new applications for drugs to treat urinary tract infections (sulopenem and tebipenem). The agency wants more data on the efficacy compared to drugs currently on the market. It’s not likely to get better anytime soon.